Figure 6 shows that the activity maintaining rate of modification by SC-mPEG10k and ALD-mPEG10k were not high, and the tumor inhibition rate of SC-mPEG10k-HM-3 (20.27%) was lower than ALD-mPEG10k-HM-3 (31.64%), while the modified product of SC-mPEG20k-HM-3 (50.23%) was excellent, displaying similar tumor inhibitory activity in vivo to the Taxol and unmodified HM-3 groups. Here, CHRM3 is linked to neoplasm.